tiprankstipranks
Trending News
More News >
AnaptysBio Inc (ANAB)
NASDAQ:ANAB

AnaptysBio (ANAB) AI Stock Analysis

Compare
573 Followers

Top Page

AN

AnaptysBio

(NASDAQ:ANAB)

Rating:46Neutral
Price Target:
$20.00
▼( -2.15% Downside)
AnaptysBio's overall stock score is primarily impacted by its strong revenue growth but significant profitability challenges. The technical indicators suggest moderate positive momentum, which is a positive factor for the stock. However, valuation concerns due to negative earnings and lack of dividend yield weigh down the score. Overall, the financial performance is the most significant factor affecting the score.
Positive Factors
Clinical Trial Success
The Ph. II trial of rosnilimab in RA hit the primary endpoint and demonstrated benefit on key secondary endpoints.
Financial Prospects
ANAB announced a $75M stock repurchase program, representing roughly 12% of the primary shares outstanding.
Strategic Partnerships
GSK reported Jemperli sales significantly above the consensus, which is positive for ANAB due to their financial collaboration.
Negative Factors
Clinical Trial Challenges
ANAB announced that the Ph. IIb trial of ANB032 did not meet the primary EASI-75 endpoint nor any secondary endpoints and will discontinue further development.
Competitive Landscape
Peresolimab was discontinued in Phase 2b by Lilly due to results not aligning with those observed in Phase 2a, contrasting with ongoing trials for rosnilimab.
Financial Performance
Net loss was $38M, compared to an estimated $22M.

AnaptysBio (ANAB) vs. SPDR S&P 500 ETF (SPY)

AnaptysBio Business Overview & Revenue Model

Company DescriptionAnaptysBio, Inc. (ANAB) is a clinical-stage biotechnology company focused on the discovery and development of novel antibody product candidates for the treatment of inflammatory diseases. The company leverages its proprietary antibody discovery technology platform to create therapeutic antibodies aimed at modulating immune system pathways. AnaptysBio's core products are primarily in the areas of immunology, with a strong emphasis on conditions with unmet medical needs.
How the Company Makes MoneyAnaptysBio generates revenue primarily through strategic collaboration agreements and partnerships with larger pharmaceutical companies. These collaborations often involve upfront payments, milestone payments based on the achievement of specific development, regulatory, and sales objectives, and potential royalty payments on sales of products developed through these partnerships. Additionally, AnaptysBio may receive funding for research and development activities under these partnerships, which further supports its operations. The company's earnings are significantly influenced by the progress and success of its clinical trials, the ability to secure new partnerships, and the commercial success of any licensed products.

AnaptysBio Financial Statement Overview

Summary
AnaptysBio shows strong revenue growth but faces significant profitability challenges and a high reliance on external financing. The balance sheet indicates increasing leverage and declining equity, while cash flow statements reflect substantial negative free cash flow. The company needs to improve operational efficiency and explore revenue growth opportunities to achieve financial sustainability.
Income Statement
45
Neutral
AnaptysBio has experienced significant revenue growth from $17.16M in 2023 to $91.28M in 2024, marking a sharp increase. However, the company has consistently reported negative net income, with a net loss of $145.23M in 2024, which indicates ongoing profitability challenges. Gross profit margin remains strong at 100% due to revenue equaling gross profit, but high operating losses are a concern.
Balance Sheet
55
Neutral
The company's balance sheet reveals a high debt-to-equity ratio of approximately 0.23 and a decreasing equity base. The equity ratio has decreased from 63.6% in 2020 to 14.6% in 2024, indicating increased leverage. Despite this, the company maintains a strong cash position, which provides some financial flexibility.
Cash Flow
42
Neutral
AnaptysBio's cash flow statement highlights a deteriorating free cash flow, with a negative free cash flow of $135.7M in 2024. The operating cash flow to net income ratio is negative, indicating that operating activities are not generating enough cash to support net losses. However, cash inflows from financing activities provide temporary liquidity support.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
91.28M17.16M10.29M63.17M75.00M
Gross Profit
91.28M14.78M7.95M-35.32M-5.03M
EBIT
-114.95M-164.41M-115.15M-56.81M-23.88M
EBITDA
-92.74M-143.16M-105.26M-55.71M-19.37M
Net Income Common Stockholders
-145.23M-163.62M-128.72M-57.19M-19.92M
Balance SheetCash, Cash Equivalents and Short-Term Investments
385.37M390.90M441.24M548.10M393.65M
Total Assets
483.83M452.39M610.38M643.07M416.55M
Total Debt
16.04M17.81M19.45M20.95M342.00K
Net Debt
-107.04M-18.15M-51.86M-474.77M-250.11M
Total Liabilities
412.97M364.29M348.28M286.64M19.82M
Stockholders Equity
70.87M88.10M262.10M356.43M396.73M
Cash FlowFree Cash Flow
-135.69M-121.61M-73.95M-47.29M-14.73M
Operating Cash Flow
-135.34M-120.80M-73.59M-45.92M-14.16M
Investing Cash Flow
95.40M144.75M-394.85M38.84M94.47M
Financing Cash Flow
127.05M-59.30M44.02M252.30M-879.00K

AnaptysBio Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price20.44
Price Trends
50DMA
19.26
Positive
100DMA
17.79
Positive
200DMA
23.30
Negative
Market Momentum
MACD
0.33
Positive
RSI
52.68
Neutral
STOCH
60.55
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANAB, the sentiment is Neutral. The current price of 20.44 is below the 20-day moving average (MA) of 20.57, above the 50-day MA of 19.26, and below the 200-day MA of 23.30, indicating a neutral trend. The MACD of 0.33 indicates Positive momentum. The RSI at 52.68 is Neutral, neither overbought nor oversold. The STOCH value of 60.55 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for ANAB.

AnaptysBio Risk Analysis

AnaptysBio disclosed 55 risk factors in its most recent earnings report. AnaptysBio reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 1 New Risks
1.
Our internal computer systems, or those of our third-party collaborators or other service providers, may fail or suffer security breaches and cyber-attacks, which could result in a material disruption of our development programs. Q4, 2024

AnaptysBio Peers Comparison

Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
72
Outperform
$719.85M-6.33%23.92%-27.69%
55
Neutral
$639.97M-55.12%-60.26%
53
Neutral
$5.14B3.23-45.01%2.85%17.55%-0.69%
49
Neutral
$621.12M53.85-4.52%92.31%78.17%
46
Neutral
$600.54M-343.83%387.20%21.00%
46
Neutral
$490.86M-75.77%-44.25%
45
Neutral
$529.54M-43.77%20.38%-194.93%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
ANAB
AnaptysBio
20.44
-2.92
-12.50%
SVRA
Savara
2.84
-1.31
-31.57%
TRVI
Trevi Therapeutics
6.29
3.73
145.70%
IMTX
Immatics
5.11
-6.56
-56.21%
PHAR
Pharming Group
10.38
1.33
14.70%
VALN
Valneva
6.18
-2.47
-28.55%

AnaptysBio Corporate Events

Product-Related Announcements
AnaptysBio Announces Promising Phase 2b RENOIR Trial Results
Positive
Feb 12, 2025

On February 12, 2025, AnaptysBio announced significant results from its Phase 2b RENOIR trial for rosnilimab in treating moderate-to-severe rheumatoid arthritis. The trial demonstrated efficacy in key endpoints, including a significant reduction in DAS-28 CRP scores and high CDAI LDA responses, with favorable safety and tolerability profiles, marking a promising advancement in RA treatment.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.